☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Renal Cancer
Telix Receives the US FDA's Breakthrough Therapy Designation for TLX250-CDx (89Zr-girentuximab)
July 1, 2020
Load more...
Back to Home